Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?
Open Access
- 18 February 2020
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (2) , 554
Abstract
From monoclonal antibodies (mAbs) to Chimeric Antigen Receptor (CAR) T cells, immunotherapies have enhanced the efficacy of treatments against B cell malignancies. The same has not been true for Acute Myeloid Leukemia (AML). Hematologic toxicity has limited the potential of modern immunotherapies for AML at preclinical and clinical levels. Gemtuzumab Ozogamicin has demonstrated hematologic toxicity, but the challenge of preserving normal hematopoiesis has become more apparent with the development of increasingly potent immunotherapies. To date, no single surface molecule has been identified that is able to differentiate AML from Hematopoietic Stem and Progenitor Cells (HSPC). Attempts have been made to spare hematopoiesis by targeting molecules expressed only on later myeloid progenitors as well as AML or using toxins that selectively kill AML over HSPC. Other strategies include targeting aberrantly expressed lymphoid molecules or only targeting monocyte-associated proteins in AML with monocytic differentiation. Recently, some groups have accepted that stem cell transplantation is required to access potent AML immunotherapy and envision it as a rescue to avoid severe hematologic toxicity. Whether it will ever be possible to differentiate AML from HSPC using surface molecules is unclear. Unless true specific AML surface targets are discovered, stem cell transplantation could be required to harness the true potential of immunotherapy in AML.Keywords
Funding Information
- National Health and Medical Research Council (543727, APP1134202)
This publication has 107 references indexed in Scilit:
- T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemiaBlood, 2013
- SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLBlood, 2013
- CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic LeukemiaPLOS ONE, 2013
- Transferred WT1-Reactive CD8 + T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant PatientsScience Translational Medicine, 2013
- Acute myeloid leukemia in the real world: why population-based registries are neededBlood, 2012
- Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaJournal of Clinical Oncology, 2011
- Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction FailureJournal of Clinical Oncology, 2010
- Monoclonal antibodies against IREM-1: potential for targeted therapy of AMLLeukemia, 2009
- CD70 as a therapeutic target in human malignanciesExpert Opinion on Therapeutic Targets, 2008
- C-Type Lectin-Like Molecule-1Cancer Research, 2004